This study is the first to propose that EphA2 plays a role in promoting cancer through the CXCL11/PD-L1 pathway in cervical cancer, which opens up new possibilities for targeted therapy and combined therapy of cervical carcinoma. Here, CXCL11 is linked to cervical carcinoma.